Contrasting Nutriband (NASDAQ:NTRB) & Century Therapeutics (NASDAQ:IPSC)

Nutriband (NASDAQ:NTRB) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Earnings & Valuation

This table compares Nutriband and Century Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.14 million	40.87	-$10.48 million	($2.87)	-2.53
Century Therapeutics	$6.59 million	6.35	-$126.57 million	($0.29)	-1.67

Nutriband has higher earnings, but lower revenue than Century Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nutriband and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-398.29%	-85.40%	-73.45%
Century Therapeutics	-19.10%	-11.53%	-6.94%

Insider and Institutional Ownership

19.7% of Nutriband shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 54.1% of Nutriband shares are held by company insiders. Comparatively, 5.0% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Nutriband has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Nutriband and Century Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	0	1	0	2.00
Century Therapeutics	0	0	4	0	3.00

Nutriband currently has a consensus price target of $13.00, suggesting a potential upside of 78.82%. Century Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 673.99%. Given Century Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Nutriband.

Summary

Century Therapeutics beats Nutriband on 11 of the 14 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.